Phase 2 Myelodysplasia Clinical Trials
10 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–10 of 10 trials
Recruiting
Phase 2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled346 locationsNCT05564390
Recruiting
Phase 2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Acute Myeloid LeukemiaAcute Myeloid Leukemia Post Cytotoxic TherapyAcute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm+1 more
National Cancer Institute (NCI)335 enrolled220 locationsNCT05554406
Recruiting
Phase 2
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+21 more
Masonic Cancer Center, University of Minnesota70 enrolled1 locationNCT05735717
Recruiting
Phase 2
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
LeukemiaChronic Myelomonocytic LeukemiaMyelodysplasia
Hannah Choe, MD124 enrolled1 locationNCT07249346
Recruiting
Phase 2
Personalized NK Cell Therapy in CBT
Acute Lymphoblastic LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia+23 more
M.D. Anderson Cancer Center100 enrolled1 locationNCT02727803
Recruiting
Phase 2
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic Leukemia+13 more
Masonic Cancer Center, University of Minnesota300 enrolled1 locationNCT03314974
Not Yet Recruiting
Phase 2
ALLG MDS05 (MYDAS-T)/D3 (MESSAGE): Myelodysplasia Advancing Strategies in Therapy platform trial - Mesenchymal signal targeting in Myelodysplasia as a pathway to transfusion independence and blood count improvement
Myelodysplasia
Australasian Leukaemia and Lymphoma Group (ALLG)30 enrolled1 locationACTRN12625000201471
Recruiting
Phase 2
A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS
Myelodysplastic SyndromesAcute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% BlastsMixed Myelodysplastic/Myeloproliferative Disease
Karolinska University Hospital200 enrolled1 locationNCT05788679
Recruiting
Phase 2
Advancing treatment therapies in Myelodysplasia
Myelodysplasia
Australasian Leukaemia and Lymphoma Group (ALLG)1,000 enrolled1 locationACTRN12622000410752
Recruiting
Phase 2
A dose determining trial to assess the recommended dose of ES-3000 and ASTX727 for patients with Myelodysplasia
Myelodysplasia
Australasian Leukaemia and Lymphoma Group32 enrolled5 locationsACTRN12621001713886